Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088478 · ClinicalTrials.gov registry record · Phase 3
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00088478: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00088478 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 402 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088478, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
Key objectives of this clinical study are to: * Determine how well intramuscular (IM) olanzapine depot works compared to placebo * Evaluate the safety and tolerability of IM olanzapine depot compared to placebo * Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).
Interventions
- DRUG Placebo
- DRUG Intramuscular Olanzapine Depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00088478 record still lists
NCT00088478 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00088478 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088478 about?
NCT00088478 is a clinical study titled "Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia". Key objectives of this clinical study are to: * Determine how well intramuscular (IM) olanzapine depot works compared to placebo * Evaluate the safety and tolerability of IM olanzapine depot compared to placebo * Evaluate different doses of IM olanzapine depot compared to placebo to identify the be...
What is the current status of trial NCT00088478?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2004-06. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00088478?
The interventions under investigation include: Placebo (DRUG), Intramuscular Olanzapine Depot (DRUG).
Who is sponsoring clinical trial NCT00088478?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088478's enrollment target sits among peer trials
402 919th of 2000 higher than 1,080 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia